Related Experiment Video

Updated: Apr 11, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

[Positive effect of low-activity thromboxane A synthase gene on prognosis in coronary heart disease]

F Yu Kopylov1, D F Mesitskaya1, Yu M Nikitina1

  • 1I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia.

Terapevticheskii Arkhiv
|June 2, 2015
PubMed

Insights

The Thromboxane A synthase 1 (TBS1) gene polymorphism AA allele may protect against clopidogrel resistance and cardiovascular events. This finding offers insights into personalized antiplatelet therapy for coronary heart disease patients.

Area of Science:

  • Pharmacogenetics
  • Cardiovascular Medicine
  • Clinical Pharmacology

Background:

  • Clopidogrel is a widely used antiplatelet medication.
  • Individual responses to clopidogrel can vary, leading to resistance.
  • Pharmacogenetic factors are increasingly recognized as influencing drug efficacy and safety.

Purpose of the Study:

  • To investigate the impact of Thromboxane A synthase 1 (TBS1) gene polymorphism on clopidogrel resistance.
  • To assess the association between TBS1 gene polymorphism and cardiovascular events.
  • To analyze the influence of pharmacogenetics on clopidogrel therapy outcomes over 18 months.

Main Methods:

  • Study included 250 patients undergoing clopidogrel treatment.
  • Platelet function was assessed using optical aggregometry.
  • Thromboxane A synthase 1 (TBS1) gene polymorphism was genotyped in all participants.

Main Results:

  • Carriage of the TBS1 gene polymorphism AA was associated with clopidogrel resistance.
  • Patients with the TBS1 gene polymorphism AA experienced fewer cardiovascular complications during the 18-month follow-up.
  • A significant protective effect was observed in AA allele carriers.

Conclusions:

  • The AA allele of the TBS1 gene appears to be a significant protective factor.
  • This genetic variant may reduce the risk of clopidogrel resistance and subsequent cardiovascular events.
  • Findings suggest potential for genotype-guided antiplatelet therapy in secondary prevention of coronary heart disease.
Abstract

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

9.0K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
602
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.0K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
91
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
125
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K